Abstract
Cyclophosphamide is an alkylating agent that has shown activity in the treatment of pediatric brain tumors, including high-grade gliomas. This study was designed to evaluate the response of patients with newly diagnosed glioblastoma multiforme to pre-radiotherapy cyclophosphamide. Fourteen patients with glioblastoma multiforme were treated with high-dose cyclophosphamide (2 g/m2/day for 2 doses every 28 days) followed by either sargramostim or filgrastin. Sargramostim was given 250 µg/m2 subcutaneously twice a day continuing through the leukocyte nadir until the absolute neutrophil count was more than 1000 cells/µl for 2 consecutive days. The filgrastin dose was 10 µg/kg given subcutaneously once daily until the post nadir absolute neutrophil count was ≥10,000 cells/µl. A total of 46 courses was given. Four patients received a total of 3 courses, 7 patients completed 4 courses and 3 patients received 2 courses. Three patients demonstrated complete response; 3 stable disease; and 8 progressive disease. The most common toxicity was hematologic, requiring platelet and packed red blood cell transfusions, with 13 admissions for neutropenia with fever. There were no deaths related to infection or bleeding. These results suggest that high-dose cyclophosphamide has modest activity with acceptable toxicity against newly diagnosed glioblastoma multiforme.
Similar content being viewed by others
References
Cohen ME, Duffner P: Supratentorial hemispheric astrocytomas. In: Cohen ME, Duffner P (eds) Brain Tumors in Children; Principles of Diagnosis and Treatment. Raven Press Ltd., New York, 1994, pp 263-284
Burger P, Green S: Patient age, histologic features and length of survival in patients with glioblastoma multiforme. Cancer 59: 1617-1625, 1987
Sposto R, Ertel I, Jenkin R, Boesel CP, Venes JL, Ortega JA, Evans AE, Wara W, Hammond D: The effectiveness of chemotherapy for treatment of high-grade astrocytoma in children: results of a randomized trial. A report from the Children's Cancer Group. J Neurooncol 7: 165-177, 1989
Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26: 239-244, 1993
Kelly KA, Kirkwood JM, Kapp DS: Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev 11(1): 1-26, Mar 1984
Marchese MJ, Chang CH: Malignant astrocytic gliomas in children. Cancer 65: 2771-2778, 1990
Bloom HJG, Glees J, Bell J: The treatment and long term prognosis of children with intracranial tumors: a study of 610 cases, 1950-1981. Int J Radiat Oncol Biol Phys 18: 723-745, 1990
Dropcho EJ, Wisoff JH, Walker RW, Allen JC: Supratentorial malignant gliomas in childhood: a review of fifty cases. Ann Neurol 22: 355-364, 1987
Duffner PK, Horowitz ME, Krischer JP, Friedman HS, Burger PC, Cohen ME, Sanford RA, Mulhern RK, James HE, Freeman CR: Postoperative chemotherapy and delayed radiation in children less than three years ofage with malignant brain tumors. N Engl J Med 328: 1725-1731, 1993
Allen JC, Helson L, Jereb B: Preradiation chemotherapy for newly diagnosed childhood brain tumors. A modified Phase II trial. Cancer 52: 2001-2006, 1983
Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M: Randomized phase III trial in childhood high-grade astroctyoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol 13: 112-123, 1995
Allen JC, Helson L: High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 55: 749-756, 1981
Friedman HS, Mahaley MS, Schold SC Jr, Vick NA, Falletta JM, Bullard DE, D'Souza BJ, Khandekar JD, Lew S, Oakes WJ: Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma. Neurosurgery 18: 335-340, 1986
Colvin M, Chabner BA: The alkylating agents. In: Chabner B (eds) Pharmacologic Principles of Cancer Treatment. WB Saunders, Philadelphia, 1990, pp 276-313
Longee DC, Friedman HS, Albright RE Jr, Burger PC, Oakes WJ, Moore JO, Schold SC Jr: Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg 72: 583-588, 1990
Lachance DH, Oette D, Schold SC Jr, Brown M, Kurtzberg J, Graham ML, Tien R, Felsberg G, Colvin OM, Moghrabi A: Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms. Med Pediatr Oncol 24: 241-247, 1995
Abrahamsen TG, Lange BJ, Packer RJ, Venzon DJ, Allen JC, Craig CE, Patronas NJ, Katz DA, Goldwein JW, Delaney TF: A phase I and II trial of dose-intensified cyclophosphamide and GM-GSF in pediatric malignant brain tumors. J Pediatr Hematol Oncol 17: 134-139, 1995
Frei E, Cannelos GP: Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585-590, 1980
Frei E, Teicher BA, Holden SA, Cathcart KN, Wang YY: Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 48: 6417-6423, 1988
Yule SM, Foreman NK, Mitchell C, Gouldon N, May P, McDowell HP: High-dose cyclophosphamide for poorprognosis and recurrent pediatric brain tumors: a doseescalation study. J Clin Oncol 15: 3258-3265, 1997
Antman KS, Griffin JD, Elias A, Socinski MA, Ryan J, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapyinduced myelosuppression. N Engl J Med 319: 593-598, 1988
Lieschke GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 327: 28-35, 1992
Dropcho EJ, Wisoff JH, Walker RW, Allen JC: Supratentorial malignant gliomas in childhood: a review of fifty cases. Ann Neurol 22: 355-364, 1987
Pool JL: The management of recurrent gliomas. Clin Neurosurg 15: 265-287, 1968
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bottom, K.S., Ashley, D.M., Friedman, H.S. et al. Evaluation of Pre-radiotherapy Cyclophosphamide in Patients with Newly Diagnosed Glioblastoma Multiforme. J Neurooncol 46, 151–156 (2000). https://doi.org/10.1023/A:1006258026274
Issue Date:
DOI: https://doi.org/10.1023/A:1006258026274